The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients

Alimentary Pharmacology and Therapeutics

Volumn 16, Issue 7, 2002, Pages 1357-1366

  Mayer, E A ^a,b,c   Berman, S ^a,b   Derbyshire, S W G ^d   Suyenobu, B ^a   Chang, L ^a,b   Fitzgerald, L ^a   Mandelkern, M ^e   Hamm, L ^f   Vogt, B ^g   Naliboff, B D ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f GLAXOSMITHKLINE   (United States)

^g Cingulum Neurosciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; SEROTONIN 3 ANTAGONIST; CARBOLINE DERIVATIVE; GASTROINTESTINAL AGENT; SEROTONIN 3 RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

ADULT; ARTICLE; BAROSTAT; BRAIN BLOOD FLOW; BRAIN FUNCTION; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EMOTION; FEMALE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; PERCEPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STIMULUS RESPONSE; BRAIN; BRAIN CIRCULATION; BRAIN LEVEL; DOUBLE BLIND PROCEDURE; METHODOLOGY; MIDDLE AGED; NOCICEPTIVE RECEPTOR; PATHOPHYSIOLOGY; RECTUM; SCINTISCANNING; STIMULATION; TREATMENT OUTCOME;

ADULT; BRAIN; BRAIN CHEMISTRY; CARBOLINES; CEREBROVASCULAR CIRCULATION; COLONIC DISEASES, FUNCTIONAL; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; NOCICEPTORS; PHYSICAL STIMULATION; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT3; RECTUM; SEROTONIN ANTAGONISTS; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 0036024228     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2002.01287.x     Document Type: Article

References (51)

1. Functional bowel disorders and functional abdominal pain
2. The impact of irritable bowel syndrome on health-related quality of life
3. Medical costs in community subjects with irritable bowel syndrome
4. Emerging disease model for functional gastrointestinal disorders
5. Stress and the gastrointestinal tract: V. Stress and irritable bowel syndrome
6. Pontine regulation of pelvic viscera: Pharmacological target for pelvic visceral dysfunction
7. Depression, anxiety and the gastrointestinal system
8. The neurobiology of stress and gastrointestinal disease
9. Regional cerebral activity in normal and pathological perception of visceral pain
10. Cerebral activation in irritable bowel syndrome patients and control subjects during rectosigmoid stimulation
11. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distension
12. Efficacy and safety of alosetron in women with irritable bowel syndrome: A randomised placebo-controlled trial
13. Satisfactory control of bowel urgency and global improvement in IBS with Lotronex® (alosetron HCl) therapy
14. Efficacy of ondansetron (GR38032F) and the role of serotonin in cisplatin-induced nausea and vomiting
15. Comparison of the 5-hydroxytryptamine (Serotonin) antagonist ondansetron (GR38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis
16. 3 receptor antagonist, on the dynamic association between bulimic behaviors and pain thresholds
17. 3 receptor antagonists and anxiety; a preclinical and clinical review
18. Pathogenetic aspects of responsiveness to ondansetron (5-hydroxytryptamine type 3 receptor antagonist) in patients with primary fibromyalgia syndrome - A preliminary study
19. 3) receptor antagonist, in the prevention of migraine attacks. A complex answer to a simple question
20. 3 receptor antagonist, in female irritable bowel syndrome patients
21. 3 receptors
22. 3H]GR65630, to rat postrema, vagus nerve and the brains of several species
23. 3 antagonist alosetron on amygdala and hippocampal activation in IBS patients
24. Irritable bowel syndrome: Guidelines for the diagnosis
25. 3 receptor antagonist
26. Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome
27. Ratio scales of sensory and affective verbal pain descriptors
28. Immunological changes in young and old adults during brief laboratory stress
29. 15O PET study
30. Statistical parametric maps in functional imaging: A general linear approach
31. The trouble with cognitive subtraction
32. The relationship between local and global changes in PET scans
33. Meta-analysis of thirty-four independent samples studied using PET reveals a significantly attenuated central response to noxious stimulation in clinical pain patients
34. 3 receptors in rat brain using radioligand binding
35. 3 receptor subtype in the rat brain and spinal cord
36. 3 receptor mRNA
37. 3 receptors and neurotransmitter release in the CNS. A nerve ending story?
38. 3 receptor-induced increases in calcium levels in individual brain nerve terminals
39. Calcium changes induced by presynaptic 5-hydroxytryptamine-3 serotonin receptors on isolated terminals from various regions of the rat brain
40. 3 receptors on presynaptic nerve terminals from rat striatum
41. Review article: Evaluation of drugs in experimental gut distension models
42. 3 receptor mediation is involved etiologically in the psychological stress lesion in the stomach of the mouse
43. Does measurement of regional cerebral blood flow reflect synaptic activity? Implications for PET and fMRI
44. Is benzodiazepine-induced amnesia due to deactivation of the left prefrontal cortex?
45. 15O positron emission tomography study
46. Alosetron does not improve anxiety in female IBS patients
47. Review article: Clinical pharmacology of alosetron
48. Review article: Roles played by 5-hydroxytryptamine in the physiology of the bowel
49. 3 receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat